John is another one of our well-recognized innovators. In 1991, he pioneered the application of signal transduction technology to understanding the mechanism of action of nongenotoxic carcinogens (epigenetic, or those that do not affect DNA). He joined us in 2002 with over 100 peer-reviewed scientific papers and 17 domestic and international patents under his belt—along with 17 years of teaching pharmacology and toxicology at Cornell University.

He's spoken at 38 national conferences on some pretty heavy topics—cytochrome P-450 mediated drug metabolism, epidemiology and molecular biology of cancer, and AIDS drug development. He also serves as the National Coordinator for the USDA Minor Species Drug Program (NRSP-7), which provides funding and expertise for the approval of antimicrobials to safely treat diseases associated with minor crop species.

But he doesn't just use his knowledge to protect food—his research includes clinical applications for it. He frequently lectures on nutrition in HIV and environmental risk assessment. And his most recent published work includes a chapter on natural antiviral products in AIDS & Alternative Medicine: Current State of the Science.

Since 1997, his work has focused on methodology for formulating novel complex mixtures of natural bioactive ingredients. With this expertise, he helped develop our ExpresSyn Process for advanced nutraceutical development.